{
  "id": "5e5d24811af46fc130000006",
  "type": "factoid",
  "question": "What is romiplostim targeting?",
  "ideal_answer": "Romiplostim (ROM) is a thrombopoietin (TPO)-receptor-agonist approved for treatment of adults with chronic immune thrombocytopenia (ITP).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29191945",
    "http://www.ncbi.nlm.nih.gov/pubmed/28548028"
  ],
  "snippets": [
    {
      "text": "Romiplostim (ROM) is a thrombopoietin (TPO)-receptor-agonist approved for treatment of adults with chronic immune thrombocytopenia (ITP).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28548028",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " the THPO-mimetic romiplostim",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29191945",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Romiplostim (ROM) is a thrombopoietin (TPO)-receptor-agonist"
}